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Abstract 
Dementia, a syndrome of cognitive decline severe enough to interfere with daily functioning 
and independent living, has been the subject of increasing focus for policymakers, civil 
organisations and multidisciplinary researchers. A substantial body of the most recent 
descriptive epidemiological research on dementia is allowing investigation of how prevalence 
and incidence might be changing across time. To establish clear trends, such comparisons 
need to be based on population-based studies using similar diagnostic and research methods 
over time. This review synthesises findings from nine prevalence trend studies and five 
incidence trend studies from western European countries (Sweden, Spain, UK, the 
Netherlands and France), the US, Japan and Nigeria. These population-based studies, apart 
from the Japanese study, have reported stable or declining prevalence and incidence and 
evidence of both inconsistent and similar changes in men and women within and across 
countries. No single risk or protective factor has been identified to fully explain these trends, 
but major societal changes in western societies and improvement in factors potentially 
associated with risk and protecting such as living conditions, higher education attainment and 
wider availability of healthcare might have favourably influenced multiple factors related to 
physical, mental and cognitive health across the lifecourse and could be responsible for this 
reduced risk of dementia in later life. Analytical epidemiologic approaches combined with 
translational neuroscientific research may provide a unique opportunity to explore underlying 
mechanisms of neuropathology and dementia in the general population. The findings from 
these studies provide robust evidence for developing fruitful avenues for prevention, 
diagnosis and treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
1.1 General 
Dementia has become an important issue in public health, economic, social and political 
domains as well as a popular research topic attracting major and increasing investment. 
Recent estimates from the World Alzheimer Report 2015 have suggested the global number of 
people with dementia is 46.8 million and is estimated to increase to 74.7 million by 2030 and 
131.5 million by 2050.1 In response to the potential dementia ‘epidemic’ and its consequent 
economic burden, the London G8 dementia summit in 2013 and the World Health 
Organisation Ministerial Conference in 2015 called for a global action against dementia and 
committed to the target of identifying a cure or disease-modifying therapy by 2025.2 To date, 
a large proportion of dementia research has focused on neurological features, 
pathophysiological mechanisms and drug discovery in order to understand the causes, 
pathology and progress of dementia and defeat this ‘one of greatest enemies of humanity’.3 
Although findings from the basic sciences have provided knowledge on dementia at the 
individual or biological level, a predominantly reductionist approach and focus on single 
mechanisms, do not suffice to understand the full spectrum of dementia in the general 
population and identify potential risk factors across different populations and life courses.4 
This can only be investigated fully through population-based epidemiological research.  
 
Population-based studies on dementia epidemiology were initiated from the 1980s onwards in 
order to assess policy development.5 These investigations started with prevalence (the 
percentage of dementia in the general population) before moving on, in longitudinal results, to 
incidence. A reasonable number of prevalence and incidence studies were carried out in 
western European countries and results from these studies contributed to the European Studies 
of Dementia (EURODEM) reports,6,7 which synthesised epidemiological measures across 
European countries with a substantial impact on policy and research. This pan-European 
collaboration has been reconvened to bring together expertise from old and new 
population-based cohorts and research resources to update dementia epidemiology for 
contemporary older European populations.8 In the US, several nationwide and regional 
cohorts of older people have included measures of cognitive function since the mid-1960s but 
the diagnosis of dementia is less often included over time in these cohorts.9 Nationwide 
estimates on prevalence have been based on results from widely varying localities with the 
higher estimate used for extrapolation to the total population in the US.10 In addition to 
western Europe and the US, a small number of epidemiological investigations have been 
conducted in Australia, Canada, Japan, China, Taiwan and other regions between the late 
1980s and the early 1990s.11 Initially and up to 2000, there was a lack of data from low and 
middle income countries but now there are many active studies in such societies.1 These 
studies have provided evidence on population metrics for dementia widely used for policy and 
lobbying for awareness and resources.  
 
Since the early studies, new generational cohorts becoming old have experienced marked 
changes in living conditions, lifestyle, access to prevention and chronic disease during their 
lifetimes. Such changes could influence dementia occurrence across generations as they can 
influence substrate and the substances of the dementia syndrome (the brain and its processes). 
 
1.2 Challenges of investigating trends in dementia occurrence 
Although descriptive population-based studies of dementia have been conducted for well over 
30 years, testing for changes across time in its prevalence or incidence through such studies 
have only emerged more recently. Despite estimates derived from statistical modelling and 
systematic reviews,1,10,11 comparable data on prevalence and incidence over time have been 
limited because studies have inconsistent and changing methodologies. There have been 
substantial changes in diagnostic criteria proposed and accepted during these decades as well 
as dramatic changes in policy practice and public recognition of dementia. Different sets of 
criteria have been long known to identify very different groups of dementia cases.13 Any 
difference in approach to diagnosis will similarly affect prevalence and incidence estimates in 
individual studies. Given these have been conducted with diverse diagnostic methods, 
different contexts and time points comparability even across geography has been challenging, 
yet along across time. These changes in diagnostic boundaries occurring in parallel with 
increasing awareness among the public and professionals has led to earlier diagnosis.14 
Conducting a consensus diagnosis, even with standardised data collection and the use of the 
same diagnostic criteria, can still be affected by changes in clinicians’ perception of diagnostic 
thresholds and criteria over time even when using the same diagnostic criteria.15,16 
Alzheimer’s type dementia is a clinically diagnosed subtype of dementia which can be made 
with variable level of investigation, now including imaging (most intensively with the 
exclusion of vascular pathologies and inclusion of Pittsburgh compound B (PIB) positive 
individuals). Whatever the intensity of investigation this clinical diagnosis is still based on an 
assumption – that the pathology ‘causing this dementia’ is Alzheimer’s type, but ultimately 
this remains heavily influenced by clinical judgement, available information on medical 
records and characteristics of study population, particularly in population-based studies. Thus, 
dementia remains a ‘clinical syndrome’ with emphasis on cognitive and functional states. 
Subtype analysis is even more difficult that the syndromic diagnosis to hold steady across 
time in order to provide any valid comparison of prevalence or incidence of subtypes. 
 
A vital need in examining changes in dementia across time is to reduce the influence of 
changes in diagnostic standards, as well as other methodological variation across time. In 
other words, it is essential to hold research methods and diagnostic approaches steady and 
therefore primary evidence has to be based on population-based studies with consistent study 
designs and measurement methods over time. Our earlier policy view focused on trends in 
dementia occurrence and summarised findings from five western European studies using 
consistent research methods across two time points in well-defined areas.12 Here we 
incorporate new population-based studies on dementia prevalence and incidence trends and 
synthesise current evidence across the globe. We investigate variations in study designs and 
methodologies across individual studies and classify primary and secondary evidence based 
on their research methods.  
 
2. Primary evidence from population-based studies 
Primary evidence testing for changes in dementia occurrence across time included 14 
population-based studies using sufficiently similar study methods at all time points in 
well-defined geographical areas for robust comparison. There were nine prevalence studies 
and five incidence studies from the US, Western Europe, Japan and Nigeria. Two Swedish 
studies17,18 were excluded from the analysis. One investigated much early prevalence and 
incidence trends from 1947-1957 and 1957-1972.17 This study was excluded as the results 
might be less relevant to contemporary older populations. The other focused on short term 
prevalence trends in very old populations aged 85 years or over in Umea, rural Sweden.18 The 
study cohorts were not sampled independently and the analysis did not take the overlapping of 
the study population into account. In addition, medical records were used to support dementia 
diagnosis and this might lead to bias due to changes in diagnostic boundaries. One Japanese 
study19 investigating prevalence trends between 1980 and 2000 was not included in primary 
evidence because the screening for dementia was based on self-reported cognitive problems 
rather than objective cognitive testing, and clinical diagnosis was only applied to those who 
reported their cognitive problems. This approach could lead to biased prevalence estimates 
because of the marked change in awareness of dementia in the population as a medical 
diagnostic entity in the recent era. There have been two reports from the Hisayama study in 
Japan.20,21 One investigated prevalence trends in the general population while the other 
focused on an autopsy subsample, which was not representative of the older population in the 
study area. The former20 was selected for this analysis. One study from China compared 
prevalence and incidence trends in dementia but used different diagnostic criteria at the two 
time points.22 This study was excluded. 
 
Studies focusing only on Alzheimer’s disease23,24 and cognitive impairment25,26 were excluded 
as the definitions and diagnostic methods are likely to be even more heterogeneous across 
time and studies. Those using medical records, healthcare administrative databases, 
systematic reviews and meta-analyses will be described briefly in the latter part of this review. 
 
2.1 Prevalence trends 
Nine studies have investigated prevalence trends in Western European countries,16,27-31 the 
US32,33 and Japan.20 Table 1 summarises study designs and methodologies of the nine 
prevalence trend studies. The earliest cohort was in the Gothenburg study (1976-1977)27 and 
the most recently reported cohort is in the Health and Retirement Study (HRS, 2012).33 The 
Cognitive Function and Ageing Studies (CFAS), Zaragoza study and Indianapolis-Ibadan 
Dementia Project (IIDP) had similar designs recruiting two independent cohorts across two 
time points in defined geographical areas.30-32 The French study focused on farmers living in 
the Bordeaux area and only included this specific occupational group for cohort comparison.16 
HRS is a dynamic cohort, enrolling new cohorts every six years in order to have a 
representative sample of older adults in the US.33 Nordanstig study28 and Stockholm study29 
compared regional prevalence in a nationwide cohort (Sweden National study on Aging and 
Care, SNAC) to earlier studies in the same localities (Nordanstig Project and Kungsholmen 
Project). The Gothenburg study27 focused on comparing age-specific prevalence at age 70 and 
75 over three decades using random samples of local populations. The only study from East 
Asia, the Hisayama study,20 included all residents aged 65 and above in the study area at four 
time points. Zaragoza, CFAS, IIDP and two Bordeaux studies all experienced considerable 
drops in response rate.30-32 To address potential selection bias due to this differential response 
rate, a wide range of sensitivity analyses was carried out in CFAS and the two Bordeaux 
studies and revealed limited impacts on the results. Despite reduction in response rate, the 
Zaragoza study used sampling strategy to take into account non-response population and 
therefore the estimates are considered to be representative to the whole older population in the 
study area. 
 
Most studies had two-stage designs, including a screening (potential cases identification) and 
a diagnostic (detailed examination and application of clinical criteria) phase while one-stage 
design (diagnosis only) was used in Gothenburg study, Nordanstig study, HRS, the second 
cohorts of Stockholm study and CFAS. Clinical diagnoses were mainly based on the 
Diagnostic and Statistical Manual of Mental Disorders, third edition revised (DSM-III-R).34 
Algorithmic diagnosis in CFAS and algorithmic historical criteria used in Gothenburg study 
were also similar to DSM-III-R. In addition to clinical diagnosis, the Bordeaux farmer study 
used an algorithm approach based on Mini-Mental State Examination (MMSE)35 and 
Instrument Activity of Daily Living (IADL)36 scores to identify potential dementia cases. The 
diagnosis in HRS was based on a 27-point cognitive test or a proxy assessment if the 
participant was not able to complete the interview.33 The assessment tool was conducted 
through phone or face to face interview and was validated in a HRS sub-sample (the Aging, 
Demographics, and Memory Study (ADAMS)), showing a 78% concordance with clinical 
diagnosis.37  
 Although these studies attempted to implement the same diagnostic methods over time, 
changes in subjective clinical opinion cannot be ruled out as a major factor which might 
influence case identification and prevalence estimates. To address this issue, Nordanstig and 
Stockholm study used the same physicians to make diagnoses in the two cohorts. IIDP used a 
clinical consensus process with the same basic group of clinicians conducting diagnoses in the 
two cohorts. CFAS and Gothenburg carried out algorithmic diagnosis using a structured 
psychiatric interview to avoid variation in subjective opinions across clinicians. Three 
studies20,29,31 had small changes in study designs and methodologies. To ensure these changes 
had minimum impact on prevalence estimates, the new measurements used in these three 
studies were tested and validated before being used on their later cohorts. 
 
Figure 1 reports the ratios of prevalence estimates in new over old cohorts by total population, 
men and women. If prevalence estimates remain the same across two cohorts, the ratio is 1.0; 
if estimates are lower in new compared to old cohorts, the ratio is smaller than 1.0. Most 
studies reported stable or declining prevalence over time and this is in contrast to the 
projected increase. The three Swedish studies generally reported stable prevalence in the total 
population with wide confidence intervals apart from the Stockholm study. CFAS reports a 
23% reduction over two decades in prevalence observed by expected total study population in 
England31 and HRS suggests a 26% decrease in the US older population over 12 years.33 The 
Bordeaux farmer study found a 40% decline in prevalence using the algorithmic diagnosis but 
an over two-fold increase in clinical diagnosis.16 The Nordanstig study and Zaragoza study 
did not report significant reductions in the total population, but over 50% decreases in 
men.28,30 Given increase in longevity of people with dementia29, these results may suggest an 
actual decline in age-specific risk of dementia. 
 
2.2 Incidence trends 
Five studies investigated incidence trends in Western Europe,38-40 the US41,42 and Nigeria41 
(Table 2). IIDP has reported trends in two samples: one was for African Americans in 
Indianapolis, US, and the other was for a Yoruba population in Ibadan, Nigeria.41 The 
Bordeaux incidence study used the same reference cohort as the prevalence study but mainly 
focused on incidence in urban residents.39 Two studies have reported both prevalence and 
incidence trends within the same study cohorts.31,32,40,41  
 
Three studies measured incidence in two independent cohorts, while the analyses of the 
Rotterdam study38 were based on non-overlapping sub-cohorts, and the analyses of the 
Framingham Heart study (FHS)42 were based on dynamic cohorts. The study population of 
Rotterdam study included all residents aged 60-90 in the study area in the 1990 cohort and a 
non-overlapping sample of all who since aged or moved into that age range and study area in 
the 2000 cohort. FHS combined the data from the Original and Off-spring cohorts and divided 
them into four epochs to compare incidence across these periods. The follow-up periods and 
intervals varied across studies, with a range from 2 years in CFAS40 to 5 years over a 30 year 
period in FHS.42 To address differential response rate and potential impact of missing data, 
several sensitivity models were tested in Bordeaux study and CFAS. 
 
Two studies used algorithmic diagnosis. Bordeaux study39 used MMSE35 and IADL36 scores 
to define dementia cases, while CFAS40 was based on a differential diagnosis derived from a 
structured psychiatric interview. The Bordeaux study also included clinical diagnosis but 
different clinical criteria were applied to the two cohorts so this was not used to assess 
temporal trends. The other three studies used clinical diagnosis based on DSM-III-R, ICD-10 
or DSM-IV.34,43,44  
 
Ratios of incidence between new and old cohorts are presented in Figure 2. Despite different 
study designs and methods, all studies suggest a potential decrease in incidence in the total 
population across cohorts and time periods. However, in the Bordeaux study this was mainly 
driven by an effect in women, whereas in CFAS the significant reduction was confined to men. 
In FHS, the substantial reduction in women occurred earlier and was sustained in the three 
epochs but in men only appeared in the last epoch. IIDP suggests a reduced incidence in 
African Americans over 10 years with an indication of a 20% reduction in Nigerian cohorts 
which did not achieve statistical significance. In the Bordeaux study, the results of clinical 
diagnosis differed from algorithm diagnosis with the latter showing a decreasing incidence.39  
 
3. Secondary evidence from other types of studies 
Secondary evidence on dementia trends included studies using medical records, healthcare 
and insurance administrative databases, systematic reviews and meta-analyses as these types 
of research are not able to control for potential changes in diagnostic methods, subjective 
clinical opinions and public awareness. Several studies from Western Europe and North 
America have reported prevalence or incidence trends based on the analyses of medical 
records and healthcare administrative databases. These studies tend to cover large populations 
and be based on their contact with medical services or outpatients over time. These analyses 
have mainly focused on short-term trends and advanced analytical strategies have been 
required to estimate prevalence or incidence rates over continuous time periods and 
overlapping study populations. Bias in ascertainment and change in diagnostic practice across 
clinical settings cannot be addressed in these analyses and this is likely to result in findings 
which are challenging to interpret. Some studies in this class have suggested stable or reduced 
trends in annual prevalence or incidence rates of dementia diagnosis25,45-49 and others have 
reported significant increases in prevalence or incidence trends.49-54 
 
Due to lack of comparable data, prevalence trends outside western countries mainly rely on 
systematic reviews and meta-analyses, which aggregate estimates across individual studies by 
the year of investigation. Systematic reviews of large number of prevalence studies in East 
Asian countries have suggested the increasing prevalence trends in Japan,55 Korea,56 Hong 
Kong,57 Taiwan,58 and China,59,60 but for China the increase loses significance when 
controlling for methodological factors including changes in diagnostic criteria.1,61,62 In 
addition, preliminary results from the Chinese Longitudinal Healthy Longevity Surveys, a 
dynamic cohort across 22 provinces in China, have in fact reported stable prevalence of 
cognitive impairment (measured by MMSE) between 1998 and 2011.63 Although it remains 
unclear whether any change in East Asia could be attributed to heterogeneity of design and 
implementation or potential differences between high and low income countries, eastern and 
western societal contexts, different results from primary investigation and systematic reviews 
may, once again, underline the substantial impact of changes in diagnostic methods and social 
contexts on prevalence estimates over time. 
 
4. Current evidence on dementia trends 
There is emerging evidence from population-based studies that have recently investigated 
changes in dementia occurrence using different approaches. Since changes in diagnostic 
methods, knowledge and public awareness all influence identification of who meets and does 
not meet study diagnostic criteria for dementia, true prevalence and incidence trends must be 
based on population-based studies using similar research methods across different time 
periods. This review includes nine prevalence studies and five incidence studies from Western 
Europe, the US, Japan and Nigeria. Many of these recent studies report decreases in response 
rates as well as change in the diagnostic boundaries that clinicians use when making 
consensus diagnosis which are likely to impact results. But despite different study designs, 
methodologies and settings across individual studies, the primary evidence generally shows 
stabilising or decreasing prevalence and incidence. This is different from the mixed findings 
reported from secondary evidence, which have been based on the analysis of healthcare 
administrative databases, medical records, systematic reviews and meta-analyses. Different 
results between clinical and algorithmic diagnoses in the two Bordeaux studies16,39 further 
emphasise the impact of changes in diagnostic boundaries and their substantial impact on 
prevalence and incidence estimates over time. Dementia diagnosis as well as diagnosis of 
other disorders is contextual, changing across time and geographies. As noted in our earlier 
review,12 it is vital that any comparison should not rely on an overview of reported numbers 
but needs to include careful appraisals of methodologies and study contexts.  
 
4.1 Potential explanations leading to changes in dementia occurrence in some western 
countries 
Although this study did not investigate mortality trends in people with dementia, a recent 
review has only identified four survival studies with limited information.64 Dementia has been 
associated with increased mortality and this difference in death rates between people with and 
without dementia may have changed over time. Given the overall mortality in the general 
population in most countries has declined over time, stable or decreasing prevalence trends 
are likely to indicate a decline of varying sizes in the incidence.  
 
New generations entering old age seem to be healthier and to have lower risk of developing 
dementia compared to earlier generations. Improvement of brain health, in terms of larger 
brain volume, less brain atrophy and cerebral small vessel disease, has been reported in the 
more recent cohort of the Rotterdam study.38 Although several possible reasons have been 
suggested to explain these encouraging findings,12,65 only four studies33,39,42,66 have identified 
the key factors associated with decreasing incidence trends (Table 3). The possible 
explanatory factors vary across American, French and Dutch cohorts. Measure of educational 
level explained varying amounts of the declining incidence trends by up to 6% in FHS cohorts 
and nearly 10% in French cohorts and in HRS controlling for education along with other 
socioeconomic factors explained 10% decrease in prevalence. In the Rotterdam study, the 
percentage of preventable dementia cases related to low education remained similar over two 
decades and this suggest education still had a large effect on dementia occurrence in the more 
recent Dutch cohort.66 Although the proportion of preventable cases due to smoking partly 
explained changes in the more recent Dutch cohort, smoking did not explain declining 
incidence in the American and French cohorts. These studies report both rising and reducing 
chronic diseases associated with dementia such as stroke, heart disease, hypertension and 
diabetes. These only explain a limited proportion of the observed reduction in incidence and 
prevalence although there would be unknown time-lags. Most treatments such as 
anti-hypertension, anti-depressants and statins have only been widely prescribed since the 
1960s. Improving treatments for cardiovascular diseases and other chronic conditions might 
change the risk of developing dementia in later life and these may have further impact in the 
future.48,67 Other lifestyle factors, such as changes in diet and physical activity, have been 
suggested to be possible reasons for declining incidence but there is currently a lack of 
primary evidence to confirm such hypotheses and these patterns are changing again in each 
successive generation. 
 
A sex difference has been found in some prevalence and incidence trend studies (Table 4). 
Three European studies have reported decreasing prevalence trends in men28,30,31 with mixed 
results for women. In incidence studies, mixed findings in men and women have been 
reported in the Rotterdam study and IIDP (no difference)38,41, CFAS (decline in men)40, the 
Bordeaux study and FHS (greater or earlier decrease in women).39,42 Life expectancy at age 
60 is a good marker of overall health status of older people in 1990, 2000 and 2012.68 
Although women had longer life expectancy at age 60 with a persistent gap over time and 
across countries, men in these western countries generally had greater increase in life 
expectancy over the most recent two decades. Decline in smoking, improvement in prevention 
and treatments for cardiovascular diseases may have had a larger impact on health and life 
expectancy in men than in women. Such major risk changes might be important in the 
observed sex difference in brain health and dementia occurrence. 
 
Although the reasons for stable or decreasing time trends are still unclear, any reduction in 
dementia occurrence is unlikely to be caused by a single risk factor. Societal changes in 
western societies after the two World Wars and improvement of living conditions have led to 
enhanced general health as well as cognitive development and reserve across the lifecourse.69 
Population level investments on infrastructures, education, health service and social welfare 
may have substantially improved multiple dimensions of physical, mental and cognitive 
health since early life with a consequence of mitigated risk of dementia in later life. For 
example, education level has been related to increase in cognitive reserve.70 Recent studies 
have reported a positive relationship with cognitive performance but not rates of decline.71 
Recent generations reaching older age have had more years of statutory education which may 
be associated with greater cognitive reserve and may in turn partly explain later dementia 
onset. Such impact on incidence trends can only be observed over decades. Addressing factors 
related to social disadvantage and health inequality may play an important role in cognitive 
health over the lifecourse. 
 
4.2 Dementia trends in other regions 
There is a lack of primary evidence outside Western Europe and the US. Although systematic 
review/meta-analysis is a possible approach to synthesise evidence on dementia epidemiology 
in low and middle income countries, any analyses of secular trends are unlikely to be robust if 
variations in methodologies and population characteristics have not been taken into account.12 
Since secondary evidence is not sufficient to inform understanding of true dementia trends, 
the discussion here only focuses on comparable primary evidence (Japan and Nigeria).  
 
Two studies beyond western Europe and the US, from Japan and Nigeria, have reported 
different trends in dementia occurrence. The Hisayama study reports an increasing prevalence 
trend between 1985 and 2005 and the autopsy subsample further suggests a higher prevalence 
in 2012.20,21 However, the analysis of the autopsy subsample did not take into account age and 
potential selection bias. Another Japanese study, which was excluded from this review due to 
particular screening approaches that do not reflect whole populations, investigated prevalence 
in all residents in Diasen-Cho area and also report an increasing prevalence across three time 
points (1980, 1990 and 2000).19 In contrast, stable incidence was found in the Nigerian 
cohorts.41 The incidence rate in the 2001 cohort was slightly lower than the 1992 cohort with 
overlapping confidence intervals.  
 
It is difficult to provide a unifying explanation for these different results as these countries 
have very different economic development, political, social and cultural backgrounds and 
pace of change over the past few decades. Figure 3 shows life expectancy at birth, an 
important indicator of general health in society, in all the countries with a prevalence or 
incidence trend study. Changes in life expectancy have been associated with substantial 
impact of societal factors and may also indicate different determinants of cognitive health 
across generations.72 Different generations and populations experience various life events, 
health status and disease profiles and trends in dementia prevalence and incidence may reflect 
complex interactions of these factors. Japan and Nigeria have dramatically different profiles 
compared to the western countries over the last century. The dramatic impact of wars on life 
expectancy can indicate extremely deprived living conditions, interruption of education and 
lack of health care in early life of the study cohorts. Life expectancy in Japan was lower than 
western countries in the first half of the 20th century and then increased dramatically in the 
1960s. Although life expectancy in Nigeria has increased by 30 years over the last century, 
there is still a 20-year gap between Nigeria and other countries. Historical or future dementia 
trends outside western countries are even less predictable because the interplay of lifecourse 
health, protective and risk factors varies so hugely across different social contexts.  
 
The longitudinal data on cardiovascular risk factors in Hisayama cohorts may provide some 
insight into potential mechanisms between chronic conditions and dementia trends within the 
Japanese context. The Hisayama study has investigated dementia prevalence in older people 
as well as vascular diseases in middle age cohorts. Since the mid-1980s, the prevalence of 
hypertension, stroke and smoking has declined, along with increasing prevalence of diabetes, 
hypercholesterolemia and obesity.73 Increasing prevalence trends of dementia might be related 
to changes in lifestyle factors including western diets and physical inactivity and rising 
obesity, metabolic syndrome and diabetes.20,74 However, an earlier analysis shows that these 
factors were not associated with an increased risk of all-type dementia after a 7-year 
follow-up. A subtype analysis only found a significant association between diabetes and 
vascular dementia, for which prevalence appeared stable across time.20,75 In more recent 
analyses of the 15-year follow-up, diabetes was related to increased risk of all type dementia 
and Alzheimer disease but not vascular dementia.76 Growing recognition of mixed dementia 
will make interpretation of any subtype changes across time even more challenging. Until 
deeper phenotyping, both in life and after death, is conducted which is consistent across time 
the detail of neurobiological changes in risk and clinical manifestation of dementia itself will 
be unknown. 
 
The four studies from the Netherlands, the US and Japan have shown somewhat different 
trends in vascular diseases, metabolic syndrome and dementia.20,38,41,42 Although population 
ageing and the increasing burden of non-communicable diseases and dementia are important 
challenges across the world, the impact of chronic diseases on dementia trends may vary 
across different contexts with uncertain and long time-lags. Forecasts for dementia burden 
need to take into account these different contexts of health profiles, deprivation and social 
environments in countries and regions rather than focusing on the potential impact of single 
risk factors.  
 
4.3 Neuroscience and epidemiology 
Current neuroscience research has largely invested in mechanistic research for treatments 
alongside searches for potential biomarkers for diagnosis of dementia subtypes, now 
preceding any clinical signs, and monitoring of treatment efficacy in highly selected clinical 
samples.77 However, it is notable that existing population-based studies in the older age 
groups have repeatedly shown serious inconsistency between cognitive performance and 
degree of neuropathology, as well as considerable overlap of pathological features in people 
with and without dementia.78,79 The new techniques for defining brain pathology and ‘normal’ 
function must be grounded through research within contemporary populations in order to 
understand the underlying neurobiology of the population changes that the studies presented 
here indicate. Observational risk factor analysis can only go so far and it needs to be 
accompanied by deep phenotyping which can be mapped back to populations. Further work is 
needed to understand the neuroscience of the gender-related differences and it is also clear 
that new cohorts in different populations such as migrants, aborigines and disadvantaged 
sectors of society will be needed.80,81  
 
The concept of population-based studies should be incorporated in future neuropathological 
research in dementia. Results from small, clinically based samples by definition have limited 
generalisability and considerable potential bias due to highly selective recruitment. In 
particular those who are socially disadvantaged are less likely to take part in such research. 
Given changes in population brain health, potential of analytical epidemiologic approaches 
and integration of neuroscience with population-based epidemiological studies 
(neuroscientific epidemiological approaches) is vitally important and provides society with a 
key opportunity to understand brain health, neurobiology and neuropathology in the general 
population in order to support better prevention, care and cure of dementia. 
 5. Conclusions 
Recent descriptive epidemiological studies have reported prevalence and incidence trends in 
dementia. Although these studies have minimised the impact of changing diagnostic criteria 
and study methods on prevalence and incidence estimates, declining response rates in recent 
cohorts remain a major challenge for future research. There is a strengthening evidence base 
that dementia, age for age, is declining in some countries and the number of people with 
dementia can remain stable despite population ageing.31,33 It is possible that substantial 
reduction in dementia risk for whole populations can balance out growing numbers of older 
people. Identifying contributing factors relevant to particular countries and regions should 
become a major priority as the findings will have important implications on health and social 
policies in relation to dementia prevention and risk reduction.  
 
Although no single factor has been identified to fully explain these changes, reduction in 
absolute inequalities including improvement in living conditions, better access to education 
and healthcare systems are likely to have influenced multiple risk and protective factors 
across the lifecourse related to physical, mental and cognitive health and thus reduced risk of 
dementia in later life. There is an important message to all in society about the long term 
action to address factors that determine both healthy and unhealthy ageing and to make 
further efforts to reduce inequalities within and across nations in expectation of health with 
age including dementia. Only an integrated approach incorporating lifecourse health bringing 
many disciplines underpinned by neuroscience and population-based epidemiological studies 
can provide the sufficiently robust evidence required to understand these changes.  
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Tables 
 
Table 1 Study designs and methodologies of the dementia prevalence studies  
Study names Study population Study designs Diagnostic methods Major changes Response to changes 
Gothenburg study,27 
Sweden 
Samples of people aged 70 and 75 
in Gothenburg 
C1: 1976-77 (N=707, R=79%) 
C2: 2000-01 (N=579, R=66%) 
C3: 2005-06 (N=753, R=63%) 
 
One-stage (diagnosis) Clinical diagnosis 
(Historical criteria, 
similar to DSM-III-R) 
(1) Subjective 
clinical opinion 
 
Nordanstig study,28 
Sweden 
Samples of people aged 78+ in 
Nordanstig 
C1: 1995-1998 (N=303, R=90%) 
C2: 2001-2003 (N=384, R=77%) 
 
One-stage (diagnosis) Clinical diagnosis 
(DSM-III-R) 
(1) Subjective 
clinical opinion 
Same physicians 
conducted diagnosis 
to reduce subjective 
clinical opinions 
 
Stockholm study,29 
Sweden 
Samples of people aged 75+ in 
Kungsholmen, Stockholm 
C1: 1987-1989 (N=1700, R=72%) 
C2: 2001-2004 (N=1575, R=73%) 
 
C1: Two-stage 
(screening + diagnosis) 
C2: One-stage 
(diagnosis) 
Clinical diagnosis 
(DSM-III-R) 
(1) Study designs 
(2) Subjective 
clinical opinions 
Same physicians 
conducted diagnosis 
to reduce subjective 
clinical opinions 
Zaragoza study,30 
Spain 
Samples of people aged 65+ in 
Zaragoza 
C1: 1987-89 (N=1080, R=95%) 
C2: 1994-96 (N=3715, R*=64%) 
 
Two-stage (screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III-R) 
(1) Response rate 
(2) Subjective 
clinical opinion 
Suggested refusals 
might not affect the 
results 
Cognitive Function 
and Ageing Study 
(CFAS),31 UK 
Samples of people aged 65+ in 
England (Newcastle, Nottingham, 
Cambridgeshire) 
C1: 1991-94 (N=7635, R=80%) 
C2: 2008-11 (N=7796, R=56%) 
 
C1: Two-stage 
(screening + diagnosis) 
C2: One-stage 
(diagnosis) 
Algorithmic diagnosis 
(GMS-AGECAT, 
similar to DSM-III-R) 
(1) Study design 
(2) Response rate 
One-stage interview 
was validated in the 
C1 follow-up. 
Sensitivity analysis 
was used to address 
low response rate in 
C2. 
 
Bordeaux farmer 
study,16 France 
 
Samples of farmers aged 65+ in 
Bordeaux 
C1: 1988-89 (N=595, R=69%) 
C2: 2007-08 (N=906, R=52%) 
 
Two-stage 
(screening + diagnosis) 
Clinical diagnosis 
(DSM-III-R) 
Algorithmic diagnosis 
(MMSE+IADL) 
(1) Subjective 
clinical opinions 
(2) Response rate 
Same physicians 
conducted consensus 
diagnosis. Sensitivity 
analysis was used to 
address low response 
rate. 
 
Health and 
Retirement Study 
(HRS)33, US 
 
Nationwide samples of people 
aged 65+ in US 
C1: 2000 (N=10546, R=88%) 
C2: 2012 (N=10516, R=89%) 
 
One-stage (diagnosis) Algorithmic diagnosis 
(Phone or facce to face 
interview using a 
27-item cognitive test 
or proxy assessment 
+IADL) 
(1) Study design 
(increased face to 
face interview in C2 
and reduced phone 
interview and proxy 
assessment) 
 
 
Indianapolis-Ibadan 
Dementia Project 
(IIDP),32 US 
Samples of African-American 
aged 70+ in Indianapolis 
C1: 1992 (N=1500, R*=86%) 
C2: 2001 (N=1892, R=44%) 
 
Two-stage (screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III-R, ICD-10) 
(1) A clinical 
consensus process 
involving clinicians 
from both sites 
(2) Response rate 
 
Same basic group of 
clinicians from both 
sites conducted the 
consensus process 
Hisayama Study,20 
Japan 
All residents aged 65+ in 
Hisayama town 
C1: 1985 (N=2457, R=95%) 
C2: 1992 (N=1189, R=97%) 
C3: 1998 (N=1437, R=100%) 
C4: 2005 (N=1566, R=92%) 
Two-stage (screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III/DSM-III-R) 
(1) Screening and 
diagnostic methods 
(2) Subjective 
clinical opinion 
Changes in 
methodologies were 
validated in cohorts. 
C1/C2/C3/C4: Cohort 1/Cohort 2/Cohort 3/Cohort 4; R: Response rate; R*: Response rate from the original 
cohorts including younger age groups (ZARADEMP-I (age 60+) and IIDP (age 65+)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Study designs and methodologies of the dementia incidence studies 
Study names Study population Follow-up Study designs Diagnostic methods Major changes Response to changes 
Rotterdam Study,38 
the Netherlands 
All residents aged 60-90 in 
Ommoord district 
C1: 1990 (N=5727, R=73%) 
C2: 2000 (N=1769, R=67%) 
 
3-4 years 
until 2007 
Two-stage 
(screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III-R) 
(1) Subjective 
clinical opinion 
 
Bordeaux Study,39 
France 
Samples of people aged 65+ in 
urban Bordeaux 
C1: 1988-89 (N=1469, R=60%) 
C2: 1999-2000 (N=2104, R=39%) 
 
Every 2-3 
years for 
10 years 
Two-stage 
(screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III-R/-IV) 
Algorithmic 
diagnosis (MMSE + 
IADL) 
(1) Diagnostic 
criteria 
(2) Response rate 
Algorithmic diagnosis 
was used to compare 
with clinical diagnosis. 
Sensitivity models were 
conducted to address 
differential response rate 
 
Cognitive Function 
and Ageing Study 
(CFAS),40 UK 
Samples of people aged 65+ in 
England (Newcastle, Nottingham, 
Cambridgeshire) 
C1: 1991-94 (N=7635, R=80%) 
C2: 2008-11 (N=7796, R=56%) 
 
2 years C1: Two-stage 
(screening + 
diagnosis) 
C2: One-stage 
(diagnosis) 
Algorithmic 
diagnosis 
(GMS-AGECAT, 
similar to 
DSM-III-R) 
(1) Study design 
(2) Response rate 
Imputation was used to 
address study design 
issue in C1. Sensitivity 
models were conducted 
to test the impact of 
missing data. 
 
Indianapolis-Ibadan 
Dementia Project 
(IIDP),41 US and 
Nigeria 
Samples of African-American 
aged 70+ in Indianapolis 
C1: 1992 (N=1440, R*=86%) 
C2: 2001 (N=1835, R=44%) 
Samples of Yoruba aged 70+ in 
Ibadan, Nigeria 
C1: 1992 (N=1174, R*=98%) 
C2: 2001 (N=1895, R=100%) 
 
Every 2-3 
years until 
2009 
Two-stage 
(screening + 
diagnosis) 
Clinical diagnosis 
(DSM-III-R, ICD-10) 
(1) A clinical 
consensus 
process involving 
clinicians from 
both sites 
(2) Response rate 
 
Same basic group of 
clinicians from both sites 
conducted the consensus 
process 
Framingham Heart 
Study (FHS),42 US 
Longitudinal cohorts of people 
aged 60+ in Framingham 
E1: 1977-83 (N=2457) 
E2: 1986-91 (N=2135) 
E3: 1992-98 (N=2333) 
E4: 2004-08 (N=2090) 
5 years Two-stage 
(screening + 
diagnosis) 
Clinical diagnosis 
(DSM-IV) 
(1) Subjective 
clinical opinion 
 
C1/C2: Cohort 1/Cohort 2; E1/E2/E3/E4: Epoch 1/2/3/4; R: Response rate; R*: Response rate from the original 
cohorts including younger age groups (IIDP (age 65+)) 
 
 
 
Table 3 Potential factors related to decreasing trends in dementia: results from Bordeaux study, 
Framingham Heart study, Health and Retirement Study and Rotterdam study 
Common risk/protective 
factors included in the 
investigations 
Analytical methods Study Results 
- Education 
- Smoking 
- Hypertension 
- Cardiovascular disease 
- Diabetes 
- BMI 
- Cholesterol levels 
 
Adjusted for different 
factors to test whether 
the decreasing 
incidence/prevalence  
was attenuated 
 
Bordeaux study,39 
France 
Education and vascular factors had a 
small effect but the decreasing trends 
remain significant. 
 
Framingham Heart 
Study,42 US 
No significant effect of all investigated 
factors (<10% changes in the trend) 
 
Health and Retirement 
Study,33 US 
Education, cardiovascular factors and 
BMI attenuated by up to 12% but the 
decreasing prevalence remain significant. 
 
Calculated population 
attributable risk (PAR)* 
for different factors in the 
two cohorts 
Rotterdam study,66 the 
Netherlands 
- Reduced PAR: smoking, cholesterol 
- Similar PAR: education, cardiovascular 
diseases 
- Increased PAR: diabetes, hypertension 
* Population attributable risk (PAR): the proportion of dementia cases that could be prevented if risk factors 
were removed.  
 
 
 
 
 
 
 
Table 4 Studies reporting sex difference in prevalence and incidence trends 
Study Prevalence trends Incidence trends Life expectancy at age 60 in years 
 Men Women Men Women Men Women 
     1990 2000 2012 1990 2000 2012 
UK: CFAS 
(2008 vs 1991) 
 * *  *  18 20 22 22 23 25 
Spain: Zaragoza 
(1994 vs 1987) 
 *  - - 19 21 22 24 25 27 
Sweden: Nordanstig 
(2001 vs 1995) 
 *  - - 19 21 23 23 24 25 
France: Bordeaux 
(1999 vs 1988) 
- -   * 20 20 23 25 26 27 
US: FHS 
(2005 vs 1985) 
- -   * 19 20 21 23 23 24 
 
   Decrease;     Stable 
*Decreasing trends achieved statistical significance; life expectancy at age 60 was based on the World Health 
Organisation data 
CFAS: Cognitive Function and Ageing Study; FHS: Framingham Heart Study; Stockholm study, Rotterdam 
study, Bordeaux farmer study, Health and Retirement study, Indianapolis-Ibadan Dementia Project (IIDP) and 
Hisayama study did not report any difference. 
 
 
 
 
 
 
 
 
Figure 1 Odds ratio and prevalence ratio reported from the eight prevalence trend studies of dementia 
  
 
 
1. The figure reports the ratios of prevalence estimates and 95% confidence intervals in new over old cohorts by 
total population, men and women. If prevalence estimates remain the same across two cohorts, the ratio is 1.0; if 
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estimates are higher in new compared to old cohorts, the ratio is greater than 1.0. 
2. HRS and Gothenburg study: unadjusted; IIDP: adjusted for age; Nordanstig, Zaragoza, Bordeaux farmer and 
Hisayama study: adjusted for age and sex; Stockholm study: adjusted for age, sex and education; CFAS: adjusted 
for age, sex, area and deprivation;  
3. Bordeaux farmer study: clinical diagnosis was conducted by neuropsychologists using DSM-IIIR criteria; 
algorithmic diagnosis was based on cognitive and functional ability tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Hazard ratio and incidence rate ratio from the five incidence trend studies of dementia 
 
 
1. The figure reports the ratios of incidence estimates and 95% confidence intervals in new over old cohorts by 
total population, men and women. If incidence estimates remain the same across two cohorts, the ratio is 1.0; if 
estimates are higher in new compared to old cohorts, the ratio is greater than 1.0. 
2. Rotterdam study, IIDP and Bordeaux study: adjusted for age; Framingham Heart study: adjusted for age and 
sex; CFAS: adjusted for age, sex, area and deprivation 
3. Bordeaux study: clinical diagnosis was conducted by neuropsychologists and neurologists using DSM-IIIR and 
DSM-V criteria; algorithmic diagnosis was based on cognitive and functional ability tests 
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